Thymosin Alpha-1 (TA-1)
Boosts immune system function naturally
- Immune System Regulation
- Chronic Infections
- Autoimmune Support
Individuals with autoimmune conditions should exercise caution due to potential for immune modulation effects Not FDA-approved in the United States — regulatory status varies by country Long-term safety data in healthy individuals using TA-1 for wellness or anti-aging purposes is lacking
Mechanism of Action
Thymosin Alpha-1 is a 28-amino acid peptide naturally produced by the thymus gland that modulates immune function primarily by enhancing dendritic cell maturation and promoting T-lymphocyte differentiation and activation. It acts through Toll-like receptor 9 (TLR9) signaling on plasmacytoid dendritic cells and stimulates the differentiation of CD4+ and CD8+ T cells from progenitor cells, while also modulating cytokine production toward a Th1-dominant response. Key Pathways: TLR9 signaling in plasmacytoid dendritic cells, T-cell maturation and differentiation (CD4+/CD8+ development), Th1/Th2 cytokine balance modulation (IL-2, IFN-α, IFN-γ upregulation), Natural killer cell activation, MHC class I expression enhancement The immune-modulating effects translate clinically to enhanced clearance of viral infections (particularly hepatitis B and C) and improved immune reconstitution in immunocompromised states. TA-1 appears to restore balance rather than simply stimulate immunity, which may explain its utility in both infection and certain autoimmune contexts where immune dysregulation is present.
Common Dose Reference Ranges
Educational reference ranges only — discuss actual dosing with a qualified healthcare provider.
Full Thymosin Alpha-1 (TA-1) protocols — frequency, timing, cycle length, reconstitution & research
- Injection site reactions
- Fatigue
- Mild flu-like symptoms
- Headache
- Theoretical autoimmune exacerbation
- Allergic reactions